PLEASANTON, Calif. , March 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas ® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test...
INDIANAPOLIS , March 18, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S . Food and Drug Administration (FDA) has categorized its Ionify® steroid assays...
BASEL, Switzerland , March 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark approval for its Elecsys ® Apolipoprotein E4 biomarker test...
With oil prices soaring near $100 per barrel, certain sectors are feeling more pain than others. Here are three ETFs to avoid amid oil's market roil.
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed ...
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms ...
– Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value
BASEL, Switzerland , March 5, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today findings from a global survey of 4,326 people with diabetes across 22 countries, exploring the...
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with...
– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s...